Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of AP306 in hemodialysis patients with hyperphosphatemia
CTR20261756Phase 2Active
- Sponsor
- Likang Life Sciences
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of EOS789 in hyperphosphatemia, sponsored by Likang Life Sciences. Started Jul 2026; status: active.
02
Drugs
EOS789
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on CTR20261756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261756.